Publications
(Partial Listing)
Glesby MJ, Hoover DR, Vaamonde CM. Osteonecrosis in patients infected with human immunodeficiency virus infection: a case-control study. J Infect Dis 2001;184:519-23.
Allison GT, Bostrom MP, Glesby MJ. Osteonecrosis in human immunodeficiency virus disease: epidemiology, etiologies, and clinical management. AIDS 2003;17:1-9.
Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ, for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy. Recommendations of the HIV Medical Association of the Infectious Diseases Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-27.
Yoon C, Gulick RM, Hoover DR, Vaamonde CM, Glesby MJ. Case-control study of diabetes mellitus in HIV-infected patients. J Acquir Immune Defic Syndr 2004;37:1464-69.
Glesby MJ, Hoover DR, Tan T, Shi Q, Gao W, French AL, Maurer T, Young M, DeHovitz J, Ru J, Anastos K. Herpes zoster in women with and at risk for human immunodeficiency virus infection: Data from the Women#146;s Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 37:1604-09.
Glesby MJ, Bassett R, Alston B, Fichtenbaum C, Jacobson EL, Owens S, Race E, Sherman K for the ACTG A5088 team. Pilot study of low dose interleukin-2, pegylated interferon-alfa2b, and ribavirin for the treatment of hepatitis C virus infection in patients with human immunodeficiency virus infection. J Infect Dis 2005;191:686-93.
Glesby MJ, Aberg JA, Kendall MA, Fichtenbaum CJ, Hafner R, Hall S, Grosskopf N, Zolopa AR, Gerber JG, for the Adult AIDS Clinical Trials Group A5159 Protocol Team. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005;78:143-53.
Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ. Histologic findings and clinical characteristics associated with hepatic steatosis in HIV/HCV coinfected patients. J Infect Dis 2005;192:1943-9.
Caskey MF, Morgan DJ, Porto AF, Giozza SP, Muniz AL, Orge GO, Travassos MJ, Barrón Y, Carvalho EM , Glesby MJ. Clinical manifestations associated with HTLV-I infection: a cross-sectional study. AIDS Res Hum Retroviruses 2007: 23:365-71.
Glesby MJ, Hoover DR, Raiszadeh F, Lee I, Shi Q, Milne G, Sanchez SC, Gao W, Kaplan RC, Morrow JD, Anastos K. Oxidant stress inHIV-infected women from the Women's Interagency HIV Study. Antivir Ther 2009;14:763-9.
Tien PC, Schneider MF, Cox C, Cohen M, Karim R, Lazar J, Young M, Glesby MJ. HIV, highly active antiretroviral therapy and lipoparticle concentrations in the Women's Intragency HIV Study. AIDS 2010;24:2809-17.
Brown TT, Glesby MJ. Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol 2011;8:11-21.
Vorkas CK, Vaamonde CM, Glesby MJ. Testosterone replacement therapy and polycythemia in HIV-infected patients. AIDS 2012;26:243-5.
Book/Book Chapters:
Glesby MJ. Toxicities and Adverse Findings Associated with Protease Inhibitors. In: Protease Inhibitors in AIDS Therapy. R Ogden, CW Flexner eds. Marcel Dekker, Inc., New York, pp 237-256, 2001.
Glesby MJ. Treatment of HIV-Associated Lipodystrophy. UptoDate.com
Ogedegbe A, Glesby MJ. Differential Diagnosis and Management of Opportunistic Infections Complicating HIV Infection. In: Clinical Infectious Disease, D Schlossberg, ed. Cambridge University Press, New York, pp 707-720, 2008.
Marks KM, Glesby MJ. Drugs to Treat Viral Hepatitis. In: Infectious Diseases, third edition, J Cohen, WG Powderly eds. Elsevier Science, London, pp 1471-76, 2010.
Glesby MJ. HIV and Cardiovascular Risk [book], Oxford University Press, New York, 2010.
